The abstract is read at the publisher; the summary is JClub's.
GalNAc-conjugated siRNA targeting Aass rescues lethality in neonatal Gcdh-/- mice and improves brain pathology while lowering toxic metabolites.
- Why it matters: GA-1 remains high risk despite early diagnosis and diet, with about one-third of patients developing progressive neurological complications.
- What they did: Neonatal Gcdh-/- mice received liver-targeted GalNAc-conjugated siRNA against Aass, and outcomes were tracked using brain and organ metabolite levels plus serum biomarkers.
- The result: Serum glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine predicted neurological outcomes, and urinary excretion stayed elevated despite lower systemic metabolite concentrations, supporting therapeutic monitoring.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.